Tumor DNA methylation profiling of patients with Adamantinomatous craniopharyngioma (ACP)

Abnormal DNA methylation plays a role in tumor progression and is becoming recognized as a prognostic marker in various types of cancers. In this study, we aimed to investigate the association between DNA methylation and clinicopathological features, prognosis, and outcomes in patients with Adamantinomatous craniopharyngioma (ACPs). To achieve this, we analyzed the global methylation profile of 35 tumors using the Illumina Infinium HumanMethylation850 BeadChip. DNA from 35 microdissected, fresh frozen tumor samples from was extracted using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. DNA was commisioned to the University of Southern California Keck Genomics Platform (Los Angeles, CA, USA), where it was bisulfite-converted using tht EZ DNA methylation kit (Zymo Research, Irvine, CA) , as provided by the manufacturer, and hybridized to the Illumina Infinium HumanMethylation850 BeadChip as specified by Illumina.